retatrutide type 2 diabetes trial results 2024 2025 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Lilly's triple agonist, retatrutide, demonstrated
Pay in 4 interest-free payments of $5.96 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24



:max_bytes(150000):strip_icc()/GettyImages-161140672-5a133d99ec2f64003728582d.jpg)




















